Share This Page
Suppliers and packagers for TOBRAMYCIN SULFATE (PHARMACY BULK)
✉ Email this page to a colleague
TOBRAMYCIN SULFATE (PHARMACY BULK)
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Gland | TOBRAMYCIN SULFATE (PHARMACY BULK) | tobramycin sulfate | INJECTABLE;INJECTION | 209346 | ANDA | Gland Pharma Limited | 68083-241-01 | 1 VIAL, PHARMACY BULK PACKAGE in 1 CARTON (68083-241-01) / 50 mL in 1 VIAL, PHARMACY BULK PACKAGE | 2021-02-09 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Tobramycin Sulfate (Pharmacy Bulk) Suppliers: Who Manufactures the Bulk API and What to Check Before Sourcing
Tobramycin sulfate “pharmacy bulk” sourcing typically refers to bulk tobramycin sulfate drug substance (API), supplied by specialized API manufacturers or toll manufacturers under GMP. The supply base for tobramycin sulfate is concentrated in a small set of generic/API producers; distributor catalogs often relabel the same underlying API.
Who supplies tobramycin sulfate (pharmacy bulk) and how do API vs distributor listings work?
Answer: Tobramycin sulfate pharmacy bulk is commonly supplied as tobramycin sulfate API by API manufacturers, then resold by pharma distributors under their own catalog numbers. The most reliable sourcing path is to require a current Certificate of Analysis, GMP status, DMF/CEP linkage (if applicable), and full traceability by batch.
API manufacturers vs distributors: what changes in due diligence?
- API manufacturers (GMP drug substance sites): Provide full C of A and manufacturing batch traceability directly from the production site; often link to a DMF (Drug Master File) or CEP (Certificate of Suitability).
- Distributors (catalog sellers): Commonly do not produce API; they source from one or more manufacturers and resell. They can be fast, but you must confirm the actual manufacturer of record for each batch.
What to request to confirm a “real” supplier
- Drug Substance (API) GMP certificate for the manufacturing site.
- Manufacturer of record for the specific batch COA you will receive.
- Analytical package: HPLC assay, impurity profile, specific rotation (if relevant), residual solvents/halides as applicable.
- Regulatory dossier linkage: DMF number or CEP/EDQM certificate reference if you are filing for regulated manufacture.
- Stability and retest specs for tobramycin sulfate bulk storage and re-test intervals.
Which companies make tobramycin sulfate API for bulk supply?
Answer: The tobramycin sulfate API supply chain is dominated by established generic API producers with aminoglycoside production capabilities. For “pharmacy bulk,” the practical approach is to source from GMP API manufacturers known to produce tobramycin sulfate, or from distributors that explicitly disclose the underlying API manufacturer for each batch.
Typical supplier profile for aminoglycoside APIs
- Multi-product sterile/aminoglycoside capable API sites
- GMP production and QC release testing for assay and related impurities
- Ability to support customer regulatory needs through DMF/CEP (where used)
Commercial reality for bulk procurement
- Multiple distributors may offer “tobramycin sulfate pharmacy bulk” but share the same upstream API.
- Differences often show up in: impurity specs, particle size/control, drying method, retest dating, and documentation completeness.
How do you qualify tobramycin sulfate (pharmacy bulk) suppliers for GMP manufacture?
Answer: Qualify using document-first and batch-based verification: GMP status of the API manufacturer, full COA, impurity profile alignment to your specification, and stability/retest compliance.
Supplier qualification checklist (high-impact items)
- Site GMP status for drug substance manufacturing
- Batch comparability: assay, key impurities, and water content (as specified)
- Impurity control strategy: aminoglycoside APIs can have distinct related-substance patterns depending on synthesis and crystallization
- Microbial limits: often less critical for API but can matter depending on downstream use and your specification
- Packaging and chain-of-custody: moisture protection and handling controls
What specifications should procurement require for tobramycin sulfate bulk API?
Answer: At minimum, you should lock down your acceptance criteria for identity, assay, impurities, and physical properties appropriate to downstream formulation.
Specification areas that materially affect downstream performance
- Identity (e.g., chromatographic identity, salts)
- Assay potency (tobramycin sulfate content)
- Related substances/impurity profile (HPLC method comparability)
- Loss on drying/water content (tobramycin sulfate can be sensitive to moisture)
- Sulfate content / salt form confirmation if your downstream requires a specific salt specification
What are the main regulatory and documentation requirements for tobramycin sulfate bulk sourcing?
Answer: Regulated manufacturing typically requires DMF/CEP alignment, GMP compliance, and batch traceability, especially if the API is used to produce a dosage form you will market.
Typical documentation artifacts
- DMF reference (where used by finished dose manufacturers)
- CEP certificate and inspection scope (if applicable)
- GMP certificate for API manufacturing site
- COA with full impurity panel
- TSE/BSE statements (if used in your compliance framework)
- Residual solvent declarations (where applicable)
What generic and hospital pharmacy risks exist if you choose the wrong tobramycin sulfate supplier?
Answer: The highest risks are specification mismatch, inconsistent impurity profile, moisture sensitivity issues, and documentation gaps that block release or regulatory filing.
Risk categories by stage
- Incoming quality risk: assay drift, out-of-spec related substances, unexpected water content
- Regulatory risk: inability to reference or justify API equivalency (DMF/CEP mismatch)
- Supply continuity risk: distributor supply disruptions when upstream capacity tightens
How does tobramycin sulfate bulk supply differ by country and sourcing model?
Answer: Bulk supply availability varies by upstream capacity and compliance posture in the exporting countries. Distributor availability is global, but API-manufacturing compliance remains localized.
Sourcing models to consider (procurement lens)
- Direct API manufacturing procurement (lowest “middle layers,” highest traceability)
- Distributor procurement with confirmed manufacturer of record (faster but depends on disclosure)
- Toll-manufactured batches under shared documentation (only if your QA can validate comparability)
Key Takeaways
- Tobramycin sulfate “pharmacy bulk” is usually API sold via distributor channels; the practical work is identifying and verifying the actual API manufacturer of record per batch.
- Supplier qualification hinges on GMP site status, complete COA/impurity profiles, moisture and stability controls, and dossier linkage (DMF/CEP) where required.
- Procurement risk concentrates in specification mismatch and documentation gaps that can delay release or block regulatory use.
FAQs
1) What documents should I require from a tobramycin sulfate bulk API supplier before first order?
Request the API manufacturer’s GMP certificate for the production site, batch COA with full impurity panel, and the manufacturer-of-record traceability that matches the COA you will receive.
2) How do I confirm the underlying manufacturer when buying “pharmacy bulk” tobramycin sulfate from a distributor?
Require a batch-specific declaration of the API manufacturer of record and match that to the COA and manufacturing batch traceability data.
3) What quality parameters most often cause rejection of tobramycin sulfate API batches?
Identity/assay drift, related substances/impurity profile mismatch, and moisture or loss-on-drying out-of-spec results are the most common high-impact rejection drivers.
4) Does tobramycin sulfate bulk sourcing require DMF/CEP alignment?
If your downstream process is for regulated finished products and relies on referencing dossiers, you typically need DMF/CEP alignment or equivalent regulatory documentation for the API.
5) What is the safest sourcing approach for regulated manufacturing of tobramycin-based products?
Buy from an API manufacturer or a distributor that provides batch-level manufacturer-of-record documentation plus GMP and full analytical documentation enabling comparability and release.
References
- International Council for Harmonisation (ICH). (2005). ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients. ICH.
- U.S. FDA. (n.d.). Drug Master Files (DMFs). FDA.
- EDQM. (n.d.). Certificates of Suitability (CEP) for human and veterinary use. European Directorate for the Quality of Medicines & HealthCare.
More… ↓
